Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

QCLS US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

QCLS US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Q/c Technologies, Inc.(QCLS US)

Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
Categorized

Q/c Technologies, Inc.(QCLS US)

Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
Categorized
Chronological
By Owner

Financials & Metrics

FinancialsChartingShort InterestEmployees
Chronological
By Owner

Financials & Metrics

FinancialsChartingShort InterestEmployees

SEC Filings

SEC Filings

Financials(70)

Expand
  • 10-QQ2ended 30 Jun 202612 Aug
  • 10-QQ1ended 31 Mar 202615 May
  • 10-K/AFY 2025ended 31 Dec 202529 Apr
  • 10-KFY 2025ended 31 Dec 202515 Apr
  • NT 10-KFY 2025ended 31 Dec 202531 Mar
  • 10-QQ3ended 30 Sept 202519 Nov 2025
  • NT 10-QQ3ended 30 Sept 202514 Nov 2025
  • 10-QQ2ended 30 Jun 202519 Aug 2025
  • NT 10-QQ2ended 30 Jun 202514 Aug 2025
  • 10-QQ1ended 31 Mar 202515 May 2025
  • 10-KFY 2024ended 31 Dec 202411 Apr 2025
  • NT 10-KFY 2024ended 31 Dec 202431 Mar 2025
  • 10-QQ3ended 30 Sept 202414 Nov 2024
  • 10-QQ2ended 30 Jun 202419 Aug 2024
  • NT 10-QQ2ended 30 Jun 202414 Aug 2024

Events(169)

Expand
  • 8-KNotice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing05:00PM
  • 8-KEntry into a Material Definitive Agreement18 Sep
  • 8-KTermination of a Material Definitive Agreement11 Sep
  • 8-KTermination of a Material Definitive Agreement2 Jul
  • 8-KChanges in Registrant's Certifying Accountant13 Mar
  • 8-KEntry into a Material Definitive Agreement23 Jan
  • 8-KEntry into a Material Definitive Agreement9 Dec 2025
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers14 Nov 2025
  • 8-K/ADirector/Officer Changes & Compensatory Arrangements6 Oct 2025
  • 8-KEntry into Material Agreement3 Oct 2025
  • 8-KCharter/Bylaw Amendment; Fiscal Year Change26 Sep 2025
  • 8-KEntry into Material Agreement10 Sep 2025
  • 8-K/AFinancial Statements and Exhibits5 Sep 2025
  • 8-KEntry into Material Agreement2 Sep 2025
  • 8-KMaterial Modification to Security Holders' Rights6 Jun 2025

Insider Ownership(132)

Expand
  • Form 4Silverman Joshua2 Oct
  • Form 4/ASilverman Joshua2 Oct
  • Form 3Ehrlichman Yossef22 Sep
  • Form 3Fagan Charles Todd17 Aug
  • Form 4Voss Chelsea Sierra14 May
  • Form 4Friscia Stephen15 Apr
  • Form 4Voss Chelsea Sierra15 Apr
  • Form 4Glass Mitchell15 Apr
  • Form 4White Billy Joe15 Apr
  • Form 4Bernstein Bruce15 Apr
  • Form 4Silverman Joshua15 Apr
  • Form 4Voss Chelsea Sierra30 Jan
  • Form 3Voss Chelsea Sierra30 Jan
  • Form 4PharmaCyte Biotech, Inc.18 Nov 2025
  • Form 4Glass Mitchell17 Nov 2025

Beneficial Ownership(39)

Expand
  • SC 13D/AQ/C TECHNOLOGIES, INC.18 Nov 2025
  • SC 13G/ATNF Pharmaceuticals, Inc.14 Nov 2024
  • SC 13DMyMD Pharmaceuticals, Inc.30 May 2024
  • SC 13GMyMD Pharmaceuticals, Inc.14 Feb 2024
  • SC 13G/AMyMD Pharmaceuticals, Inc.14 Feb 2024
  • SC 13G/AMyMD Pharmaceuticals, Inc.14 Feb 2023
  • SC 13DMyMD Pharmaceuticals, Inc.8 Sep 2022
  • SC 13G/AMyMD Pharmaceuticals, Inc.23 Feb 2022
  • SC 13G/AMyMD Pharmaceuticals, Inc.11 Feb 2022
  • SC 13G/AMyMD Pharmaceuticals, Inc.11 Jan 2022
  • SC 13DMyMD Pharmaceuticals, Inc.27 Apr 2021
  • SC 13G/AAkers Biosciences, Inc.22 Feb 2021
  • SC 13GAkers Biosciences, Inc.18 Feb 2021
  • SC 13G/AAkers Biosciences, Inc.29 Jan 2021
  • SC 13GAkers Biosciences, Inc.20 Nov 2020

Proxies(41)

Expand
  • DEF 14ADefinitive proxy statement20 Oct 2025
  • PRE 14APreliminary proxy statement10 Oct 2025
  • DEFR14ADefinitive revised proxy statement19 May 2025
  • PRER14APreliminary proxy statement (revision)9 May 2025
  • ARSAnnual report to security holders21 Apr 2025
  • DEF 14ADefinitive proxy statement21 Apr 2025
  • PRE 14APreliminary proxy statement11 Apr 2025
  • DEF 14ADefinitive proxy statement1 Nov 2024
  • ARSAnnual report to security holders1 Nov 2024
  • DEF 14ADefinitive proxy statement1 Jul 2024
  • PRE 14APreliminary proxy statement20 Jun 2024
  • DEFA14ADefinitive additional materials21 Jul 2023
  • ARSAnnual report to security holders30 Jun 2023
  • DEF 14ADefinitive proxy statement30 Jun 2023
  • PRE 14APreliminary proxy statement20 Jun 2023

Registrations(72)

Expand
  • S-3Registration statement (primary offering)11 Feb
  • DRSDraft registration statement23 Jan
  • 424B3Prospectus filing (Rule 424(b)(3))1 Dec 2025
  • S-3Registration statement (primary offering)3 Oct 2025
  • 424B3Prospectus filing (Rule 424(b)(3))12 Aug 2024
  • S-3/ARegistration statement (primary offering, amendment)8 Aug 2024
  • S-3Registration statement (primary offering)21 Jun 2024
  • 424B5Prospectus filing (Rule 424(b)(5))23 Feb 2023
  • 424B5Prospectus filing (Rule 424(b)(5))17 Aug 2022
  • S-8Registration statement (employee benefit plan)5 Jul 2022
  • 424B3Prospectus filing (Rule 424(b)(3))11 May 2021
  • S-3/ARegistration statement (primary offering, amendment)28 Apr 2021
  • Form 425Business combination communication13 Apr 2021
  • Form 425Business combination communication12 Apr 2021
  • S-3Registration statement (primary offering)25 Mar 2021

Filing Review Correspondence(31)

Expand
  • CORRESPFiling review correspondence12 Feb
  • CORRESPFiling review correspondence25 Nov 2025
  • CORRESPFiling review correspondence19 Aug 2025
  • CORRESPFiling review correspondence30 Sep 2024
  • CORRESPFiling review correspondence9 Aug 2024
  • CORRESPFiling review correspondence10 May 2021
  • CORRESPFiling review correspondence28 Apr 2021
  • CORRESPFiling review correspondence19 Mar 2021
  • CORRESPFiling review correspondence24 Aug 2020
  • CORRESPFiling review correspondence23 Jul 2020
  • CORRESPFiling review correspondence21 Jul 2020
  • CORRESPFiling review correspondence10 Jun 2020
  • CORRESPFiling review correspondence5 Jun 2020
  • CORRESPFiling review correspondence6 Apr 2020
  • CORRESPFiling review correspondence24 Mar 2020

SEC Orders And Notices(13)

Expand
  • EFFECTNotice of effectiveness18 Feb
  • EFFECTNotice of effectiveness1 Dec 2025
  • EFFECTNotice of effectiveness12 Aug 2024
  • EFFECTNotice of effectiveness11 May 2021
  • EFFECTNotice of effectiveness23 Mar 2021
  • EFFECTNotice of effectiveness25 Aug 2020
  • EFFECTNotice of effectiveness12 Jun 2020
  • EFFECTNotice of effectiveness7 Apr 2020
  • EFFECTNotice of effectiveness5 Dec 2019
  • EFFECTNotice of effectiveness18 Dec 2017
  • EFFECTNotice of effectiveness30 Jun 2017
  • EFFECTNotice of effectiveness16 Nov 2016
  • EFFECTNotice of effectiveness23 Jan 2014

Exempt Offerings(10)

Expand
  • D06b5 Sep 2025
  • D06b31 May 2024
  • D06b31 May 2024
  • D06b24 Nov 2020
  • D06b11 Aug 2020
  • D06b21 May 2020
  • D06b14 Apr 2020
  • D06b7 Apr 2020
  • D06b13 Apr 2017
  • D<ITEMS>06b

Other(1)

Expand
  • CERTNASAUTO-GENERATED PAPER DOCUMENT22 Jan 2014

Financials(70)

Expand
  • 10-QQ2ended 30 Jun 202612 Aug
  • 10-QQ1ended 31 Mar 202615 May
  • 10-K/AFY 2025ended 31 Dec 202529 Apr
  • 10-KFY 2025ended 31 Dec 202515 Apr
  • NT 10-KFY 2025ended 31 Dec 202531 Mar
  • 10-QQ3ended 30 Sept 202519 Nov 2025
  • NT 10-QQ3ended 30 Sept 202514 Nov 2025
  • 10-QQ2ended 30 Jun 202519 Aug 2025
  • NT 10-QQ2ended 30 Jun 202514 Aug 2025
  • 10-QQ1ended 31 Mar 202515 May 2025
  • 10-KFY 2024ended 31 Dec 202411 Apr 2025
  • NT 10-KFY 2024ended 31 Dec 202431 Mar 2025
  • 10-QQ3ended 30 Sept 202414 Nov 2024
  • 10-QQ2ended 30 Jun 202419 Aug 2024
  • NT 10-QQ2ended 30 Jun 202414 Aug 2024

Events(169)

Expand
  • 8-KNotice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing05:00PM
  • 8-KEntry into a Material Definitive Agreement18 Sep
  • 8-KTermination of a Material Definitive Agreement11 Sep
  • 8-KTermination of a Material Definitive Agreement2 Jul
  • 8-KChanges in Registrant's Certifying Accountant13 Mar
  • 8-KEntry into a Material Definitive Agreement23 Jan
  • 8-KEntry into a Material Definitive Agreement9 Dec 2025
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers14 Nov 2025
  • 8-K/ADirector/Officer Changes & Compensatory Arrangements6 Oct 2025
  • 8-KEntry into Material Agreement3 Oct 2025
  • 8-KCharter/Bylaw Amendment; Fiscal Year Change26 Sep 2025
  • 8-KEntry into Material Agreement10 Sep 2025
  • 8-K/AFinancial Statements and Exhibits5 Sep 2025
  • 8-KEntry into Material Agreement2 Sep 2025
  • 8-KMaterial Modification to Security Holders' Rights6 Jun 2025

Insider Ownership(132)

Expand
  • Form 4Silverman Joshua2 Oct
  • Form 4/ASilverman Joshua2 Oct
  • Form 3Ehrlichman Yossef22 Sep
  • Form 3Fagan Charles Todd17 Aug
  • Form 4Voss Chelsea Sierra14 May
  • Form 4Friscia Stephen15 Apr
  • Form 4Voss Chelsea Sierra15 Apr
  • Form 4Glass Mitchell15 Apr
  • Form 4White Billy Joe15 Apr
  • Form 4Bernstein Bruce15 Apr
  • Form 4Silverman Joshua15 Apr
  • Form 4Voss Chelsea Sierra30 Jan
  • Form 3Voss Chelsea Sierra30 Jan
  • Form 4PharmaCyte Biotech, Inc.18 Nov 2025
  • Form 4Glass Mitchell17 Nov 2025

Beneficial Ownership(39)

Expand
  • SC 13D/AQ/C TECHNOLOGIES, INC.18 Nov 2025
  • SC 13G/ATNF Pharmaceuticals, Inc.14 Nov 2024
  • SC 13DMyMD Pharmaceuticals, Inc.30 May 2024
  • SC 13GMyMD Pharmaceuticals, Inc.14 Feb 2024
  • SC 13G/AMyMD Pharmaceuticals, Inc.14 Feb 2024
  • SC 13G/AMyMD Pharmaceuticals, Inc.14 Feb 2023
  • SC 13DMyMD Pharmaceuticals, Inc.8 Sep 2022
  • SC 13G/AMyMD Pharmaceuticals, Inc.23 Feb 2022
  • SC 13G/AMyMD Pharmaceuticals, Inc.11 Feb 2022
  • SC 13G/AMyMD Pharmaceuticals, Inc.11 Jan 2022
  • SC 13DMyMD Pharmaceuticals, Inc.27 Apr 2021
  • SC 13G/AAkers Biosciences, Inc.22 Feb 2021
  • SC 13GAkers Biosciences, Inc.18 Feb 2021
  • SC 13G/AAkers Biosciences, Inc.29 Jan 2021
  • SC 13GAkers Biosciences, Inc.20 Nov 2020

Proxies(41)

Expand
  • DEF 14ADefinitive proxy statement20 Oct 2025
  • PRE 14APreliminary proxy statement10 Oct 2025
  • DEFR14ADefinitive revised proxy statement19 May 2025
  • PRER14APreliminary proxy statement (revision)9 May 2025
  • ARSAnnual report to security holders21 Apr 2025
  • DEF 14ADefinitive proxy statement21 Apr 2025
  • PRE 14APreliminary proxy statement11 Apr 2025
  • DEF 14ADefinitive proxy statement1 Nov 2024
  • ARSAnnual report to security holders1 Nov 2024
  • DEF 14ADefinitive proxy statement1 Jul 2024
  • PRE 14APreliminary proxy statement20 Jun 2024
  • DEFA14ADefinitive additional materials21 Jul 2023
  • ARSAnnual report to security holders30 Jun 2023
  • DEF 14ADefinitive proxy statement30 Jun 2023
  • PRE 14APreliminary proxy statement20 Jun 2023

Registrations(72)

Expand
  • S-3Registration statement (primary offering)11 Feb
  • DRSDraft registration statement23 Jan
  • 424B3Prospectus filing (Rule 424(b)(3))1 Dec 2025
  • S-3Registration statement (primary offering)3 Oct 2025
  • 424B3Prospectus filing (Rule 424(b)(3))12 Aug 2024
  • S-3/ARegistration statement (primary offering, amendment)8 Aug 2024
  • S-3Registration statement (primary offering)21 Jun 2024
  • 424B5Prospectus filing (Rule 424(b)(5))23 Feb 2023
  • 424B5Prospectus filing (Rule 424(b)(5))17 Aug 2022
  • S-8Registration statement (employee benefit plan)5 Jul 2022
  • 424B3Prospectus filing (Rule 424(b)(3))11 May 2021
  • S-3/ARegistration statement (primary offering, amendment)28 Apr 2021
  • Form 425Business combination communication13 Apr 2021
  • Form 425Business combination communication12 Apr 2021
  • S-3Registration statement (primary offering)25 Mar 2021

Filing Review Correspondence(31)

Expand
  • CORRESPFiling review correspondence12 Feb
  • CORRESPFiling review correspondence25 Nov 2025
  • CORRESPFiling review correspondence19 Aug 2025
  • CORRESPFiling review correspondence30 Sep 2024
  • CORRESPFiling review correspondence9 Aug 2024
  • CORRESPFiling review correspondence10 May 2021
  • CORRESPFiling review correspondence28 Apr 2021
  • CORRESPFiling review correspondence19 Mar 2021
  • CORRESPFiling review correspondence24 Aug 2020
  • CORRESPFiling review correspondence23 Jul 2020
  • CORRESPFiling review correspondence21 Jul 2020
  • CORRESPFiling review correspondence10 Jun 2020
  • CORRESPFiling review correspondence5 Jun 2020
  • CORRESPFiling review correspondence6 Apr 2020
  • CORRESPFiling review correspondence24 Mar 2020

SEC Orders And Notices(13)

Expand
  • EFFECTNotice of effectiveness18 Feb
  • EFFECTNotice of effectiveness1 Dec 2025
  • EFFECTNotice of effectiveness12 Aug 2024
  • EFFECTNotice of effectiveness11 May 2021
  • EFFECTNotice of effectiveness23 Mar 2021
  • EFFECTNotice of effectiveness25 Aug 2020
  • EFFECTNotice of effectiveness12 Jun 2020
  • EFFECTNotice of effectiveness7 Apr 2020
  • EFFECTNotice of effectiveness5 Dec 2019
  • EFFECTNotice of effectiveness18 Dec 2017
  • EFFECTNotice of effectiveness30 Jun 2017
  • EFFECTNotice of effectiveness16 Nov 2016
  • EFFECTNotice of effectiveness23 Jan 2014

Exempt Offerings(10)

Expand
  • D06b5 Sep 2025
  • D06b31 May 2024
  • D06b31 May 2024
  • D06b24 Nov 2020
  • D06b11 Aug 2020
  • D06b21 May 2020
  • D06b14 Apr 2020
  • D06b7 Apr 2020
  • D06b13 Apr 2017
  • D<ITEMS>06b

Other(1)

Expand
  • CERTNASAUTO-GENERATED PAPER DOCUMENT22 Jan 2014